| 2025-01-24 |
Taiho Oncology, Inc. |
Taiho Oncology Presents Real-World Findings for LONSURF® at the ASCO Gastrointestinal Cancers Symposium taihooncology.com ↗ |
| 2023-08-02 |
Taiho Oncology, Inc. |
FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC) taihooncology.com ↗ |
| 2023-05-03 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier Announce Publication in the New England Journal of Medicine of Pivotal Phase 3 Data for Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer taihooncology.com ↗ |
| 2023-04-18 |
Taiho Oncology, Inc. |
U.S. Food and Drug Administration Accepts for Priority Review Taiho Oncology’s Supplemental New Drug Application for the Use of Trifluridine/Tipiracil (LONSURF®) in Combination With Bevacizumab for Refractory Metastatic Colorectal Cancer taihooncology.com ↗ |
| 2023-01-17 |
Taiho Oncology, Inc. |
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium taihooncology.com ↗ |
| 2021-02-04 |
Taiho Oncology, Inc. |
National Comprehensive Cancer Network® Provides Updates on Use of LONSURF® (trifluridine and tipiracil) in NCCN Drugs and Biologics Compendium® for Colon Cancer and Rectal Cancer taihooncology.com ↗ |
| 2021-01-12 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier To Present Data on LONSURF® (trifluridine and tipiracil) at 2021 ASCO Gastrointestinal Cancers Symposium (ASCO GI) taihooncology.com ↗ |
| 2020-01-25 |
Taiho Oncology, Inc. |
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Futibatinib (TAS-120) at ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) taihooncology.com ↗ |
| 2019-10-14 |
Taiho Oncology, Inc. |
Analysis of Patients with Prior Gastrectomy Treated with LONSURF® (trifluridine and tipiracil) Published in JAMA Oncology taihooncology.com ↗ |
| 2019-06-03 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting taihooncology.com ↗ |
| 2019-02-25 |
Taiho Oncology, Inc. |
FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma taihooncology.com ↗ |
| 2019-01-17 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier Present Data on LONSURF® (trifluridine/tipiracil) at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI) taihooncology.com ↗ |
| 2018-10-25 |
Taiho Oncology, Inc. |
FDA Accepts Supplemental New Drug Application for LONSURF® (trifluridine/tipiracil) for the Treatment of Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma; Grants Priority Review taihooncology.com ↗ |
| 2018-10-21 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier Announce Positive Results from LONSURF® (trifluridine/tipiracil) Study Presented at ESMO 2018 Congress and Published in The Lancet Oncology taihooncology.com ↗ |
| 2018-09-28 |
Taiho Oncology, Inc. |
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium taihooncology.com ↗ |
| 2018-06-21 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018 taihooncology.com ↗ |
| 2018-06-14 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018 taihooncology.com ↗ |
| 2018-06-07 |
Taiho Oncology, Inc. |
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil) taihooncology.com ↗ |
| 2018-05-09 |
Taiho Oncology, Inc. |
Taiho Oncology Announces Positive Topline Results from Pivotal Phase 3 Trial of LONSURF® (trifluridine/tipiracil) in Metastatic Gastric Cancer taihooncology.com ↗ |
| 2018-04-13 |
Taiho Oncology, Inc. |
Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compounds at the 109th Annual Meeting of the American Association for Cancer Research taihooncology.com ↗ |
| 2018-01-20 |
Taiho Oncology, Inc. |
Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Metastatic Colorectal Cancer (mCRC) Data at ASCO 2018 Gastrointestinal Cancers Symposium taihooncology.com ↗ |
| 2018-01-12 |
Taiho Oncology, Inc. |
Taiho Oncology Announces Multiple LONSURF® (trifluridine and tipiracil) Presentations at ASCO 2018 Gastrointestinal Cancers Symposium taihooncology.com ↗ |
| 2015-09-29 |
Taiho Oncology, Inc. |
Taiho Oncology, Inc. Announces Comprehensive Access Support Program for LONSURF® (trifluridine and tipiracil) taihooncology.com ↗ |
| 2015-09-22 |
Taiho Oncology, Inc. |
Taiho Oncology, Inc. Announces FDA Approval of LONSURF® (trifluridine and tipiracil) for Refractory Metastatic Colorectal Cancer (mCRC) taihooncology.com ↗ |
|